TRAVERSE: Transseptal vs Retrograde Aortic Ventricular Entry

Summary

The purpose of this study is to compare two methods that are each routinely performed as standards of care (a transseptal approach versus a retrograde approach) of performing a procedure, called ablation, to treat abnormal heart rhythm. The study aims to determine the effects that the two methods may have on preventing brain problems. Participants will still have the medical procedure they are already planning to have (catheter ablation) to help treat abnormal heart rhythm. They will be randomly assigned to 1 of 2 study groups; one group will have the transseptal approach (Method 1), and the other group will have the retrograde approach (Method 2) performed in the ablation procedure.


Inclusion Criteria

  • Men and women ≥ 18 years of age
  • Planned/scheduled endocardial ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure
  • For this patient, the current plan of the operator must be to pursue a catheter ablation target in the left ventricular endocardium that can be accessed by either a transseptal puncture or retrograde aortic approach
  • Life expectancy of at least 1 year
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli Multi-center comparative effectiveness randomized clinical trial to assess a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia and/or premature ventricular contractions

Details
Disease Type/Condition

Cardiac Surgery

Principal Investigator

Ehdaie, Ashkan

Age Group

Adult

Phase

N/A

IRB Number

STUDY00000523

ClinicalTrials.gov ID

NCT03946072

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Cardiac Surgery

Principal Investigator

Ehdaie, Ashkan

Age Group

Adult

Phase

N/A

IRB Number

IIT-EHDAIE-2020-TRAVERSE

ClinicalTrials.gov ID

NCT03946072

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?